Other mutations in p53 pathway, such as the amplification of MDM2 (a negative regulator of p53) [70] or dysregulation of mir-34 (a microRNA regulated by p53), also promote ovarian, prostate, and breast cancers [71,72,73]. This evidence concerns the gene TP53 and breast carcinoma.